Evidence map›Paper›PMID 36700242›Full record

ArticleBone reports2023

Assessment of DXA derived bone quality indexes and bone geometry parameters in early breast cancer patients: A single center cross-sectional study.

Rebecca Pedersini, Deborah Cosentini, Luca Rinaudo, Manuel Zamparini, Fabio Massimo Ulivieri, Pierluigi di Mauro, Filippo Maffezzoni, Sara Monteverdi, Walter Vena, Lara Laini and 5 more

Open access · goldAbstract read
In one paragraph

Article in Bone reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 1 country.

Rebecca PedersiniMedical Oncology, ASST Spedali Civili, Brescia, Italy.
Deborah CosentiniMedical Oncology, ASST Spedali Civili, Brescia, Italy.
Luca RinaudoTecnologie Avanzate Srl, Turin, Italy.
Manuel ZampariniMedical Oncology, ASST Spedali Civili, Brescia, Italy.
Fabio Massimo UlivieriCasa di Cura la Madonnina, Milano, Italy.
Pierluigi di MauroMedical Oncology, ASST Spedali Civili, Brescia, Italy.
Filippo MaffezzoniBreast Unit, ASST Spedali Civili, Brescia, Italy.
Sara MonteverdiSanta Chiara Hospital, Trento, Italy.
Walter VenaEndocrinology, Diabetology and Medical Andrology Unit, Metabolic Bone Diseases and Osteoporosis Section, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy.
Lara LainiMedical Oncology, ASST Spedali Civili, Brescia, Italy.
Vito AmorosoMedical Oncology, ASST Spedali Civili, Brescia, Italy.
Edda Lucia SimonciniBreast Unit, ASST Spedali Civili, Brescia, Italy.
Davide FarinaDepartment of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST Spedali Civili, Brescia, Italy.
Gherardo MazziottiDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy.
Alfredo BerrutiMedical Oncology, ASST Spedali Civili, Brescia, Italy.
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITCasa di Cura Columbus · ITHumanitas University · ITIRCCS Humanitas Research Hospital · ITOspedale Santa Chiara · ITTecnologie Avanzate (Italy) · ITUniversity of Brescia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Bone mineral density (BMD) lacks sensitivity in individual fracture risk assessment in early breast cancer (EBC) patients treated with aromatase inhibitors (AIs). New dual-energy X-ray absorptiometry (DXA) based risk factors are needed. Methods: Trabecular bone score (TBS), bone strain index (BSI) and DXA parameters of bone geometry were evaluated in postmenopausal women diagnosed with EBC. The aim was to explore their association with morphometric vertebral fractures (VFs). Subjects were categorized in 3 groups in order to evaluate the impact of AIs and denosumab on bone geometry: AI-naive, AI-treated minus (AIDen-) or plus (AIDen+) denosumab. Results: A total of 610 EBC patients entered the study: 305 were AI-naive, 187 AIDen-, and 118 AIDen+. In the AI-naive group, the presence of VFs was associated with lower total hip BMD and T-score and higher femoral BSI. As regards as bone geometry parameters, AI-naive fractured patients reported a significant increase in femoral narrow neck (NN) endocortical width, femoral NN subperiosteal width, intertrochanteric buckling ratio (BR), intertrochanteric endocortical width, femoral shaft (FS) BR and endocortical width, as compared to non-fractured patients. Intertrochanteric BR and intertrochanteric cortical thickness significantly increased in the presence of VFs in AIDen- patients, not in AIDen+ ones. An increase in cross-sectional area and cross-sectional moment of inertia, both intertrochanteric and at FS, significantly correlated with VFs only in AIDen+. No association with VFs was found for either lumbar BSI or TBS in all groups. Conclusions: Bone geometry parameters are variably associated with VFs in EBC patients, either AI-naive or AI treated in combination with denosumab. These data suggest a tailored choice of fracture risk parameters in the 3 subgroups of EBC patients.

Indexed as

AI, aromatase inhibitorAIDen+, aromatase inhibitor with denosumabAIDen-, aromatase inhibitor without denosumabAromatase inhibitorsBMD, bone mineral densityBMI, body-mass indexBone strain indexBR, buckling ratioBSI, bone strain indexCSA, cross-sectional areaCSMI, cross-sectional moment of inertiaDual-energy X-ray absorptiometryDXA, dual-energy X-ray absorptiometryEBC, early breast cancerFS, femoral shaftHAL, hip axis lengthHR, hormone receptorHSA, Hip Structure AnalysisIT, intertrochantericNN, narrow neckNSA, neck shaft anglePS, propensity scoreROC, receiver operator characteristicTBS, trabecular bone scoreVertebral fracturesVF, vertebral fractureZ, modulus

Identifiers

PMID36700242
PMCPMC9868326
OpenAlexW4315471253

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.